
Quarterly report 2025-Q3
added 11-13-2025
Milestone Scientific Revenue 2011-2026 | MLSS
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Milestone Scientific
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.63 M | 9.83 M | 8.81 M | 10.3 M | 5.44 M | 8.37 M | 9.62 M | 11.3 M | 10.5 M | 9.49 M | 10.3 M | 10 M | 8.65 M | 8.38 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11.3 M | 5.44 M | 9.26 M |
Quarterly Revenue Milestone Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.36 M | 2.32 M | 2.23 M | - | 2.51 M | 1.85 M | 2.25 M | - | 2.06 M | 2.91 M | 2.6 M | - | 2.22 M | 1.65 M | 2.7 M | - | -69.9 K | -95.9 K | 1.3 K | - | - | - | 1.81 M | - | 49.1 K | 58.7 K | 9.56 K | - | 259 K | 78.6 K | 36.8 K | - | 2.85 M | 15.5 K | -44.4 K | - | -253 K | -57.9 K | -270 K | - | -711 K | -690 K | -358 K | - | -224 K | -213 K | 2.62 M | - | -212 K | -47.1 K | 2.49 M | - | - | -46.1 K | -78.1 K | - | -60 K | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.91 M | -711 K | 863 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical instruments industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
169 M | - | - | $ 810 M | ||
|
Baxter International
BAX
|
2.75 B | $ 20.07 | - | $ 10.2 B | ||
|
Luminex Corporation
LMNX
|
417 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
1.58 M | - | -9.52 % | $ 20.6 M | ||
|
Antares Pharma, Inc.
ATRS
|
150 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
1.02 B | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
106 M | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
2.88 B | - | -0.05 % | $ 10.3 B | ||
|
Varian Medical Systems, Inc.
VAR
|
3.17 B | - | -0.02 % | $ 16.3 B | ||
|
Ekso Bionics Holdings
EKSO
|
17.9 M | $ 8.7 | - | $ 175 M | ||
|
ICU Medical
ICUI
|
2.38 B | $ 149.9 | - | $ 3.66 B | ||
|
Alcon
ALC
|
9.91 B | $ 80.98 | - | $ 40.4 B | ||
|
InfuSystem Holdings
INFU
|
110 M | $ 8.26 | - | $ 171 M | ||
|
AtriCure
ATRC
|
465 M | $ 36.93 | - | $ 1.73 B | ||
|
electroCore
ECOR
|
16 M | $ 6.66 | -6.2 % | $ 36.7 K | ||
|
Haemonetics Corporation
HAE
|
1.36 B | $ 66.66 | - | $ 3.35 B | ||
|
AngioDynamics
ANGO
|
292 M | $ 10.36 | - | $ 423 M | ||
|
The Cooper Companies
COO
|
4.09 B | $ 81.38 | 1.26 % | $ 16.2 B | ||
|
Harvard Bioscience
HBIO
|
112 M | $ 0.5 | -6.65 % | $ 21.2 M | ||
|
Merit Medical Systems
MMSI
|
1.36 B | $ 81.09 | - | $ 4.72 B | ||
|
Glaukos Corporation
GKOS
|
315 M | $ 119.38 | - | $ 5.78 B | ||
|
Isoray
ISR
|
3.55 M | - | 0.03 % | $ 108 M | ||
|
Repro Med Systems
KRMD
|
28.5 M | $ 5.39 | -1.1 % | $ 246 M | ||
|
OraSure Technologies
OSUR
|
186 M | $ 2.79 | - | $ 208 M | ||
|
iRhythm Technologies
IRTC
|
592 M | $ 154.51 | 3.7 % | $ 4.82 B | ||
|
LeMaitre Vascular
LMAT
|
220 M | $ 84.97 | - | $ 1.91 B | ||
|
Masimo Corporation
MASI
|
2.09 B | $ 137.33 | - | $ 7.32 B | ||
|
Intuitive Surgical
ISRG
|
8.35 B | $ 504.22 | - | $ 179 B | ||
|
STERIS plc
STE
|
5.46 B | $ 262.6 | - | $ 25.9 B | ||
|
Microbot Medical
MBOT
|
117 K | $ 1.8 | - | $ 18.4 M | ||
|
Nephros
NEPH
|
14.2 M | $ 4.31 | -1.82 % | $ 44.8 M | ||
|
NeuroMetrix
NURO
|
3.03 M | - | 5.05 % | $ 9.02 M | ||
|
Utah Medical Products
UTMD
|
12.3 M | $ 61.06 | - | $ 222 M | ||
|
Envista Holdings Corporation
NVST
|
2.51 B | $ 23.47 | - | $ 4.04 B | ||
|
DENTSPLY SIRONA
XRAY
|
3.79 B | $ 12.47 | - | $ 2.53 B | ||
|
Pro-Dex
PDEX
|
66.6 M | $ 39.23 | -0.44 % | $ 129 M | ||
|
Predictive Oncology
POAI
|
1.62 M | - | - | $ 31.1 M | ||
|
Pulse Biosciences
PLSE
|
700 K | $ 13.83 | - | $ 664 M | ||
|
Becton, Dickinson and Company
BDX
|
21.8 B | $ 203.48 | - | $ 58.5 B | ||
|
Repligen Corporation
RGEN
|
632 M | $ 149.37 | - | $ 8.32 M | ||
|
ResMed
RMD
|
3.58 B | $ 258.31 | 0.27 % | $ 37.7 B | ||
|
BioLife Solutions
BLFS
|
82.3 M | $ 21.8 | - | $ 1 B | ||
|
Stereotaxis
STXS
|
26.8 M | $ 2.19 | -6.01 % | $ 177 M | ||
|
Retractable Technologies
RVP
|
33 M | $ 0.7 | - | $ 21 M | ||
|
STAAR Surgical Company
STAA
|
314 M | $ 18.95 | - | $ 931 M | ||
|
Teleflex Incorporated
TFX
|
3.05 B | $ 104.37 | - | $ 4.89 B | ||
|
West Pharmaceutical Services
WST
|
2.89 B | $ 231.12 | - | $ 16.9 B |